Uscom has received a Notice of Allowance from the United States Patent Office for a new method and apparatus patent related to its novel Uscom BP+ supra-systolic oscillometric central blood pressure monitor.
The patent describes a novel method and apparatus for producing a central pressure waveform in an oscillometric blood pressure system, and is central to the technology within the Uscom BP+ central blood pressure monitor. The patent was assigned the application number 15/224,821 and was filed on 1st August 2016, with a confirmation number 3711, and provides a 20 year period of commercial protection from the date of filing.
The patented technologies within Uscom BP+ improve the measurement of blood pressure, a fundamental clinical measurement of circulation, and represent some of the most advanced and innovative of cardiovascular technologies. The central pulse pressure wave measurements generated by the BP+ have application in the diagnosis and management of hypertension, heart failure and vascular health and have only previously been available using cardiac catheters. In children the device has been called the â€œnon-invasive arterial lineâ€ for its potential to replace currently used arterial pressure catheters.The BP+ measures central and brachial blood pressure and pulse pressure waves using supra-systolic oscillometry and is currently in regulatory review for approval for sale into China, Europe and the USA, with a number of new partnerships being negotiated for international distribution. By measuring directly into the aorta rather than measuring the arm BP, the Uscom BP+ provides potentially improved blood pressure monitoring measurements, and the devices has been invasively validated against catheters in children and adults.
Executive Chairman of Uscom, Associate Professor Rob Phillips said, "Patents are real value for shareholders and recognition of innovative and practice leading science. We see the Uscom BP+ and BP+ Reporter as the disrupting technologies for blood pressure, heart failure and critical care monitoring, and this new patent adds to the others in our BP+ suite. The BP+ is currently deployed on the International Space Station to provide novel insights into the cardiovascular physiology of astronauts. The Uscom BP+ has a real role in cardiovascular practice and we anticipate its adoption will grow rapidly once global approvals are granted over the next 12 months and as new specialist distributors are appointed."
Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.